Apixaban Has Lower Bleeding Risk for Initial Anticoagulation for Venous Thromboembolism
During extended treatment, bleeding risk was similar for apixaban and rivaroxaban
During extended treatment, bleeding risk was similar for apixaban and rivaroxaban
Findings seen among adults prescribed warfarin, DOACs beyond 6 months after acute venous thromboembolism
New findings reported by Danish investigators are from the first study to demonstrate the association.
Increase seen in in-hospital mortality and 7 perioperative complications for adults undergoing major elective inpatient surgery
No reduction seen in risk of thrombotic events but increased risk of major and minor bleeding
Indefinite anticoagulation prevented recurrent VTE events, but induced major bleeding events
Systematic review showed risk for death and major bleeding complications was lower for catheter-directed thrombolysis than systemic thrombolysis
Direct oral anticoagulants noninferior to low-molecular-weight heparin for venous thromboembolism prevention
Findings seen in patients with ischemic stroke without occlusion of large or medium-sized vessels, at least one moderately to severely weak limb
Venous thromboembolism occurred in the graft in 15.4% of patients.